GlassScriptPhysician profile
Carlos A Osmon
NPI 1225033640
$10,442.82
in general payments reported to CMS, 2019-2025
34 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,461 · 2020: $216 · 2021: $18.09 · 2022: $422 · 2023: $833 · 2024: $371 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $966 · Honoraria: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $965.88 |
| Honoraria | $360.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $4,048.45 | 2019-2024 | Jakafi |
| Kite Pharma, INC. | $1,700.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,245.43 | 2019 | |
| Daiichi Sankyo INC. | $477.92 | 2019-2024 | Enhertu, Injectafer |
| Seagen INC. | $437.73 | 2019-2023 | Tukysa |
| Genentech USA, INC. | $343.55 | 2019-2022 | |
| Abbvie INC. | $305.79 | 2019-2025 | |
| Exelixis INC. | $267.09 | 2019 | |
| Merck Sharp & Dohme LLC | $190.63 | 2019-2023 | Keytruda |
| Pfizer INC. | $161.26 | 2019-2023 | |
| Beigene USA, INC. | $125.00 | 2023 | Brukinsa |
| Lilly USA, LLC | $106.63 | 2019-2024 | Verzenio, Retevmo, Jaypirca |
| Novartis Pharmaceuticals Corporation | $104.57 | 2019-2020 | |
| Tersera Therapeutics LLC | $81.92 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $76.89 | 2019-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $75.73 | 2019-2024 | Darzalex |
| Amgen INC. | $74.74 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $63.25 | 2019-2023 | Imbruvica |
| Glaxosmithkline, LLC. | $61.24 | 2023-2024 | Zejula, Jemperli, Shingrix |
| Genzyme Corporation | $51.74 | 2019 | |
| Coherus Oncology, INC. | $51.63 | 2020-2022 | |
| Eisai INC. | $50.95 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $46.87 | 2021-2024 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $45.04 | 2019-2024 | |
| Celgene Corporation | $44.55 | 2019-2024 | |
| Foundation Medicine, INC. | $32.82 | 2023 | Foundationone Liquid Cdx |
| Dendreon Pharmaceuticals LLC | $32.20 | 2023 | Provenge |
| Takeda Pharmaceuticals U.S.A., INC. | $31.52 | 2019 | |
| Stemline Therapeutics INC. | $22.28 | 2024 | Orserdu |
| Taiho Oncology, INC. | $21.43 | 2019 | |
| Jazz Pharmaceuticals INC. | $21.02 | 2019 | |
| Fortovia Therapeutics, INC. | $18.05 | 2020 | |
| Puma Biotechnology, INC. | $12.90 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Osmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.